Your browser doesn't support javascript.
loading
Heterogeneity in renal end points of cardiovascular outcomes trials in Type 2 diabetes.
Balijepalli, Chakrapani; Yan, Kevin; Zoratti, Michael; Franklin, Meg; Druyts, Eric.
Affiliation
  • Balijepalli C; Pharmalytics Group, Vancouver, BC V6B 2Z4, Canada.
  • Yan K; Pharmalytics Group, Vancouver, BC V6B 2Z4, Canada.
  • Zoratti M; Department of Health Research Methods, Evidence, & Impact, McMaster University, Hamilton, ON L8S 4L8, Canada.
  • Franklin M; Franklin Pharmaceutical Consulting LLC, Rock Hill, SC 29730, USA.
  • Druyts E; Pharmalytics Group, Vancouver, BC V6B 2Z4, Canada.
J Comp Eff Res ; 10(3): 169-173, 2021 02.
Article in En | MEDLINE | ID: mdl-33541137
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Cardiovascular System / Diabetes Mellitus, Type 2 / Kidney Failure, Chronic Limits: Humans Language: En Journal: J Comp Eff Res Year: 2021 Document type: Article Affiliation country: Canada
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Cardiovascular System / Diabetes Mellitus, Type 2 / Kidney Failure, Chronic Limits: Humans Language: En Journal: J Comp Eff Res Year: 2021 Document type: Article Affiliation country: Canada